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Background: In-stent restenosis continues to be a therapeutic challenge. The present study aimed to evaluate the safety and efficacy of a new 
drug eluting balloon Pantera Lux Paclitaxel Releasing Balloon in patients with a single in-stent restenotic lesion in coronary arteries.
Methods: Between August 17, 2009 and April 27 2010, 81 patients presenting with in-stent restenosis were treated with the Pantera Lux at 9 
European sites. Patients with a single restenotic lesion in a previously stented area, irrelevant whether bare metal or drug eluting stent presenting 
with a vessel diameter of 2 - 4 mm, and a lesion length of 8 - 28 mm were enrolled in this first in man trial. The primary endpoint was angiographic 
in-stent LLL at 6-month FUP evaluated by an independent core laboratory.
Results: Sixty-three men (77.2%) and 18 women (22.2%) with a mean age of 67 ± 9.0 yrs presented with in-stent restenosis from 44 (54.3%) bare 
metal and 37 (45.7%) drug eluting stents.





6-Month FUP N= 34
Mean + SD
Reference Vessel Diameter in mm 2.81 + 0.41 2.84 + 0.40 2.75 + 0.38
Minimum Lumen Diameter in mm 0.92 + 0.40 2.15 + 0.43 2.05 + 0.38
Diameter Stenosis in % 67.5 24.0 25.1
In-Stent Late Lumen Loss in mm 0.03 + 0.35
Major Adverse Cardiac Events at 6-month clinical follow-up is 7.7% (3/39).
Final results of the full study population will be presented during ACC.
Conclusions: Treatment of in-stent restenosis form a bare-metal or drug-eluting stent in coronary arteries with the Pantera Lux Paclitaxel Releasing 
Balloon showed excellent acute and 6-month follow-up results. However the results are based on the first 45 German patients and final results of 
the full 81 international patients will be presented at ACC.
